Promising Phase I Clinical Trial of Rogosertib Leads To
Multi-Institutional Phase II Trial
Results of a phase 1 clinical trial reported at the American
Association for Cancer Research (AACR) annual conference show that orally
administered Rigosertib is well tolerated in patients with advanced solid
tumors. This is the first trial in which orally administered Rigosertib, a dual
kinase inhibitor, was studied in solid tumors. Intravenously rigosertib is
already in phase 3 clinical trials for myelodysplastic syndrome and pancreatic
cancer and oral rigosertib is being studied in a pair of Phase II trials in
lower-risk transfusion dependent MDS patients. The drug candidate is being
developed by Onconova Therapeutics, Inc., of Pennington, NJ.
No comments:
Post a Comment